Peter Blume-Jensen, Acrivon Therapeutics CEO
Acrivon bags a megaround to advance an old Eli Lilly program, 5 months after launch. Is an IPO far behind?
Not five months after launching with an old Eli Lilly asset, Acrivon Therapeutics is already upping the ante.
The Cambridge, MA-based biotech pulled in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
